Sagimet Biosciences Inc.
SGMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $9,730 | $7,248 | $15,342 | $14,216 |
| G&A Expenses | $4,604 | $4,677 | $4,523 | $3,979 |
| SG&A Expenses | $4,604 | $4,677 | $4,523 | $3,979 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,334 | $11,925 | $19,865 | $18,195 |
| Operating Income | -$14,334 | -$11,925 | -$19,865 | -$18,195 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,426 | $1,539 | $1,689 | $1,994 |
| Pre-Tax Income | -$12,908 | -$10,386 | -$18,176 | -$16,201 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,908 | -$10,386 | -$18,176 | -$16,201 |
| % Margin | – | – | – | – |
| EPS | -0.4 | -0.32 | -0.56 | -0.5 |
| % Growth | -25% | 42.9% | -12% | – |
| EPS Diluted | -0.4 | -0.32 | -0.56 | -0.5 |
| Weighted Avg Shares Out | 32,465 | 32,195 | 32,195 | 32,195 |
| Weighted Avg Shares Out Dil | 32,465 | 32,195 | 32,195 | 32,195 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1,539 | $1,689 | $1,994 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12,908 | -$11,925 | -$19,865 | -$16,201 |
| % Margin | – | – | – | – |